Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler
  
Novo Nordisk presented more data for semaglutide in NASH at AASLD (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Therapy Areas